早期启动TNF抑制联合甲氨蝶呤治疗银屑病关节炎可提高缓解率:一项双盲随机安慰剂对照试验
该研究纳入51例未使用过甲氨蝶呤(MTX)和生物类改善病情抗风湿药(bDMARD)的活动性银屑病关节炎(PsA)患者,随机接受戈利木单抗联合MTX或安慰剂联合MTX治疗。第22周时,联合治疗组DAS缓解率为81%,显著高于MTX单药组的42%(p=0.004),且安全性相似。
要点
- 戈利木单抗联合MTX一线治疗早期PsA,第22周DAS缓解率显著优于MTX单药。
- 联合治疗组在MDA、ACR20/50/70等多项应答指标上均显著优于MTX单药组。
- 两组不良事件发生率相似,支持早期启动TNF抑制剂治疗PsA。
核心结论
- 在早期PsA患者中,戈利木单抗联合MTX治疗第22周的DAS缓解率几乎为MTX单药的两倍,支持早期启动TNF抑制剂有利于实现缓解。
研究设计与样本
- 研究者发起的多中心、双盲、随机、安慰剂对照试验,纳入51例符合CASPAR标准且基线有活动性疾病(肿胀关节计数/压痛关节计数≥3)的MTX和bDMARD初治PsA患者。
- 患者随机分配至戈利木单抗(50 mg皮下注射,每月一次)联合MTX组(n=26)或匹配安慰剂联合MTX组(n=25);MTX起始15 mg/周,8周内增至25 mg/周。
- 主要终点为第22周达到DAS缓解(<1.6)的患者百分比,研究全程评估安全性。
主要发现
- 主要疗效终点达到率在TNF抑制剂联合组为81%,MTX单药组为42%(p=0.004)。
- DAS缓解的差异在第8周即已观察到。
- 第22周时,戈利木单抗联合MTX组在MDA、ACR20/50/70、疾病活动度指标和患者报告结局等其他应答标准上也显著优于MTX单药组。
- 两组不良事件和治疗中出现的不良事件发生率相似。
关键数值与推荐
- 主要终点:第22周DAS缓解(DAS<1.6)率,戈利木单抗联合MTX组81% vs MTX单药组42%(p=0.004)。
- 入组标准:符合CASPAR分类标准、MTX和bDMARD初治、基线肿胀关节计数/压痛关节计数≥3的活动性PsA患者。
- MTX用法:起始15 mg/周,8周内增至25 mg/周;戈利木单抗50 mg皮下注射每月一次。
临床怎么用
- 对于MTX和bDMARD初治的活动性PsA患者,可考虑早期启动戈利木单抗联合MTX治疗以提高缓解率。
- 联合治疗在第8周即可显现DAS缓解优势,提示早期评估疗效的时间点可提前。
- 联合治疗安全性特征与MTX单药相似,支持在密切监测下用于早期PsA。
局限性
- 样本量较小(共51例),结果的普遍性需更大规模研究验证。
- 研究仅评估至第22周,长期疗效和安全性数据未报告。
- 研究仅使用戈利木单抗,结论外推至其他TNF抑制剂需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Early initiation of effective treatment favours remission in rheumatoid arthritis, but it remains unknown if the same concept applies to psoriatic arthritis (PsA). Therefore, this study investigated whether the combination of golimumab plus methotrexate (MTX) as a first-line treatment is superior to MTX alone in inducing remission in PsA. METHODS: This investigator-initiated, multicentre, double-blind, randomised, placebo-controlled trial included 51 MTX and bDMARD-naive patients with PsA fulfilling the CASPAR criteria and with active disease at baseline (≥3 swollen joint count/tender joint count). Patients were randomised to golimumab (50 mg SC monthly)+MTX (n=26) (TNFi arm) or matched placebo+MTX (n=25) (MTX arm). MTX was started 15 mg/week and increased to 25 mg/week over 8 weeks. The primary endpoint was percentage of patients achieving Disease Activity Score (DAS) remission (<1.6) at week 22. Safety was assessed throughout the study. RESULTS: The primary efficacy endpoint was achieved by 81% in the TNFi arm versus 42 % in the MTX arm (p=0.004). This difference in DAS remission was already observed at week 8. A significant difference in favour of the golimumab+MTX arm at week 22 was also observed for other response criteria such as MDA, ACR20/50/70, disease measures and patient-reported outcomes. The occurrence rates of adverse event and treatment-emergent adverse event were similar in both arms. CONCLUSIONS: In patients with early PsA, DAS remission at week 22 was almost doubled with golimumab+MTX versus MTX alone. This double-blind, randomised, placebo-controlled study supports the concept that early initiation of TNFi in patients with PsA favours remission. TRIAL REGISTRATION NUMBER: NCT01871649.
引用
- van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019. PMID: 30808625. doi:10.1136/annrheumdis-2018-214746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。